Fast-shifting policies and market dynamics in China, the world’s second-largest single pharma and a major consumer health market, are changing multinationals’ ways of operating locally, which is prompting a renewed look at splitting business to achieve efficiency and agility.
The world’s largest health conglomerate, Johnson & Johnson, has recently announced a planned spin-off of its consumer health business to become two separate entities, while
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?